1Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express brain EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the Brain. Glia, 2000, 30(3): 271 -278.
3Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Phannacol Sci, 2004, 25 : 577 - 583.
4Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic nuropathy. Proc Natl Acad Sci USA, 2004, 101(3) : 823 -828.
5Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int, 1999, 55:808-820.
6Fishbane S, Ragolia L, Palaia T, et al. Cytopretection by darbepoetin/epoetin affa in pig tubular and mouse mesangial cells. Kidney Int, 2004, 65 : 452 - 458.
7Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant, 2004, 19: 348 - 355.
8Yang CW, Li C, Jung J-Y, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney FASEB J, 2003, 17(12) : 1754 -1755.
9Sharplers EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol, 2004, 15:2115 -2124.
1Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express brain EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia ,2000, 30(3): 271-278.
2Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA, 2000, 97(19): 10526-10531.
3Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J, 2001, 15(10): 1804-1806.
4Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A, 2004,101(3):823-828.
5Pradat PF. Treatment of peripheral neuropathies with neurotrophic factors: animal models and clinical trials. Rev Neurol (Paris) ,2003, 159(2): 147-161.
6Conti G, Stoll G, Scarpini E, et al. p75 neurotrophin receptor induction and macrophage infiltration in peripheral nerve during experimental diabetic neuropathy: possible relevance on regeneration. Exp Neurol, 1997, 146(1):206-211.
7Conti G, Scarpini E, Baron P, et al. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1beta and p75NTR. J Neurol Sci, 2002, 195(1):35-40.
8Cameron NE, Eaton SE, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 2001, 44(11):1973-1988.
9Russell JW, Sullivan KA, Windebank AJ,et al. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis, 1999, 6(5):347-363.
10Villa P, Bigini P, Mennini T,et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med, 2003, 198(6):971-975.
8Morgera S,Heering P,Szentandraai T,et al.Erythropeietin in patients with acute renal failure and continuous veno-venous haemofiltration[J].International urology and nephrology,1997,29(2):245-250.
9Sharples EJ,Yaqoob MM.Erythropoietin and acute renal failure[J].Semin Nephrol,2006,26(4):325-331.
10Johnson DW,Forman C,Vesey DA.Novel renoprotective actions of erythropoietin:new uses for an old hormone[J].Nephrology,2006,11 (4):306-312.
